Clinical Trials · NCT00765817
Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 261
- Start date
- Oct 2008
- Locations
- 59 sites, 6 countries
- Primary endpoint
- Change in Glycosylated Hemoglobin (HbA1c)